Novo Nordisk has asked the FDA to block production of compounded copies of Ozempic, arguing that it’s too difficult to do safely. It’s the latest escalation in a brewing war between pharmaceutical companies and compounders.
Sexism within health systems means that women get worse and delayed treatment. The UK has proposed a plan that could solve this issue—experts weigh in on how to do it best.
A proposed law would tighten up phone bans in schools and limit how tech companies use children’s data, but experts are unconvinced these measures would make kids safer or healthier.
Even the makers of the Guardian Cap admit it looks silly. But for a sport facing an existential brain-injury crisis, once unthinkable solutions have now become almost normal.
Flooded households may now be at risk of mold-related illnesses following this year's hurricanes in the American South.
The death of an American woman inside Philip Nitschke’s latest invention reveals the next frontier in the right-to-die debate.
Consuming cinnamon may have a very small effect on weight, but it’s unlikely to deliver meaningful weight loss without other lifestyle adjustments.
Now that the Mounjaro and Zepbound shortage is over, Eli Lilly is going after the cottage industry selling “compounded” versions of its meds.
Mounjaro and Zepbound are now out of shortage. This should be good news—but because so many patients are taking compounded versions of these GLP-1 medications, it’s a complicated situation.
More than 200 health care facilities in impacted areas are moving patients and residents in what the state’s chief of emergency medical oversight calls “our largest evacuation ever.”
